Relapsing Remitting Multiple Sclerosis
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Previous MRI studies focused on gray matter changes only.
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Differences in gut bacteria were apparent between patients with active RRMS and those in remission.
The 2 mg dose appears to be most efficacious.
If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.
The company said it will continue to explore its options.
Notably, results were achieved without maintenance therapy.
At follow-up, 22 patients were cognitively impaired compared to 34 at baseline.
The monthly injectable comes with a boxed warning for severe liver injury.
Treatment with the biannual injection consistently resulted in greater achievement of NEDA compared to standard care.
Women who experience relapse and take corticosteroids may be at risk for complications.
No differences were observed among the group who switched therapy and controls.
Combined results confirmed that intrathecal LCN2 production was increased in MS patients, especially those with SPMS and PPMS.
Natalizumab treatment linked to 15.9% increase of value in JC virus.
When first-line therapies fail, physicians must consider several factors when choosing the next course of treatment for their RRMS patients.
The results suggest that addressing depression may help improve other symptoms, like pain and fatigue.
MS clinical trials have triple the success rate of those focused on other diseases.
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
- Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure